Trial Profile

A study assessing COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Apr 2020 According to an Emergent BioSolutions media release, company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have agreed to incorporate the company COVID-HIG product candidate into one of NIAID clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins.
26 Mar 2020 New trial record
11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com